Clearasil sales
This article was originally published in The Rose Sheet
Executive Summary
"Good progress" has been made on the integration and rejuvenation of the acne treatment brand, which contributed over $114.5 mil. (£1=$1.46) in sales worldwide in its first full year, Boots says in its fiscal 2002 financial review May 30. Operating profits for the brand rose by over 13% to $97.9 mil. for the year ended March 31 and the total investment in Clearasil reached $165.8 mil., retailer adds. In the U.S., retail sales for Clearasil were up 1% to $34.4 mil. in the 52 weeks ended April 21, according to Information Resources, Inc. data for food, drug and mass outlets, excluding Wal-Mart...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.